ArticleGlycoconjugate journal2026
Salmon proteoglycan modulates TIMP-gelatinase regulation in intestinal epithelial cells.
Article in Glycoconjugate journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chondroitin sulfate (CS) and CS proteoglycans (CSPGs) are increasingly used in nutritional and biomedical applications. Although their functional benefits have traditionally been attributed to their translocation into the bloodstream after oral administration, their poor bioavailability, due to high molecular weight and strong negative charge, has prompted substantial debate. In this study, we examined the possibility that CS and CSPG act directly on intestinal epithelial cells, thereby providing an alternative explanation for their physiological effects under non-absorptive conditions. Differentiated Caco-2 cells (human enterocyte) were employed as an in vitro model of the intestinal epithelium. Administration of CS and CSPG modulated tissue inhibitor of metalloproteinase gene expression and altered gelatinase activity in the basolateral compartment. While the two glycans shared some overlapping actions, each also exerted distinct effects reflective of their structural features. These findings suggest that CS and CSPG directly modulate epithelial signaling and reshape the basement membrane microenvironment. Overall, this study suggests a mechanism by which CS/CSPG exerts physiological actions in the intestinal tract independent of systemic absorption, providing a new perspective on the functional outcomes of oral administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.